SK bioscience Joins Sunflower Therapeutics with $2M SAFE Subscription

Share This Post

Key Highlights

  • SK bioscience subscribes to Sunflower Therapeutics’ $2M SAFE agreement.
  • Focus on developing cost-effective HPV vaccine using Pichia pastoris.
  • Sunflower’s innovative continuous fermentation and Daisy PetalTM perfusion bioreactor.
  • Enhanced vaccine manufacturing efficiency and accessibility.

Source: Business Wire

Notable Quotes

  • “Our accessible, cutting-edge protein manufacturing solutions are moving the needle by reimagining the biologic development process.”  Dr. Kerry R. Love, Founder, CEO, and President at Sunflower Therapeutics
  • “In this time where various infectious diseases threaten humanity, vaccine sovereignty is the key to protecting the safety of our people and enhancing national competition.”  Jaeyong Ahn, CEO at SK Bioscience

SoHC's Take

The collaboration between Sunflower Therapeutics and SK bioscience exemplifies the strategic partnerships necessary to revolutionize vaccine development and manufacturing. With SK bioscience’s $2M SAFE subscription, the focus on using Sunflower’s innovative biomanufacturing techniques, including continuous fermentation and the Daisy PetalTM perfusion bioreactor, positions both companies at the forefront of producing cost-effective and accessible vaccines. This partnership is a significant step toward democratizing healthcare and addressing public health crises like HPV and cervical cancer on a global scale.

More To Explore

Total
0
Share